Zu Yu Chen, DO
Family Medicine · Flushing, NYNPI 1023413747
Payments from drug & device makers
Across 332 payments — averaging $34.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Gilead$3K
- AbbVie$1K
- Novo Nordisk$736
- Boehringer Ingelheim$690
- Amarin Pharma, Inc.$402
- plus $2K from 14 others
What the payments were for
- Food & beverage$11,328100%
- Education$490%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 69 | $3,417 |
| Gilead | 91 | $3,194 |
| AbbVie | 46 | $1,132 |
| Novo Nordisk | 35 | $736 |
| Boehringer Ingelheim | 29 | $690 |
| Amarin Pharma, Inc. | 20 | $402 |
| Axsome Therapeutics, Inc. | 3 | $388 |
| Lilly USA, LLC | 12 | $338 |
| AstraZeneca | 5 | $311 |
| GSK | 7 | $161 |
| Merck | 1 | $125 |
| Pfizer | 1 | $105 |
| Johnson & Johnson | 1 | $103 |
| Phathom Pharmaceuticals, Inc. | 3 | $76 |
| E.r. Squibb & Sons, L.L.C. | 3 | $66 |
| Novartis | 2 | $54 |
| Astellas Pharma US Inc | 1 | $26 |
| Agios Pharmaceuticals, Inc. | 1 | $24 |
| Oxford Immunotec USA Inc | 1 | $19 |
| Radius Health, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,378 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Epolamine | 248 | $178,699 |
| VascepaIcosapent Ethyl | 322 | $125,072 |
| ProliaDenosumab | 47 | $79,614 |
| RybelsusSemaglutide | 77 | $77,444 |
| SynjardyEmpagliflozin/Metformin Hcl | 108 | $69,050 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 27 | $66,159 |
| LinzessLinaclotide | 117 | $63,627 |
| JardianceEmpagliflozin | 90 | $62,733 |
| UbrelvyUbrogepant | 41 | $51,825 |
| QuliptaAtogepant | 41 | $44,842 |
| CreonLipase/Protease/Amylase | 38 | $39,161 |
| VemlidyTenofovir Alafenamide | 24 | $32,415 |
| RestasisCyclosporine | 43 | $28,337 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 56 | $27,866 |
| Repatha SureclickEvolocumab | 48 | $27,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Ubrelvy, Qulipta, Creon, Restasis | $1,132 | $227,792280 claims |
| Boehringer IngelheimSynjardy, Jardiance, Synjardy Xr, Trijardy Xr, Tradjenta | $690 | $175,007278 claims |
| AmgenProlia, Evenity (2 Syringes) | $3,417 | $145,77374 claims |
| Novo NordiskRybelsus, Ozempic | $736 | $91,63692 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Nexium, Symbicort | $311 | $38,19985 claims |
| GileadVemlidy | $3,194 | $32,41524 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $161 | $31,17091 claims |
| PfizerEliquis | $105 | $26,56033 claims |
| Johnson & JohnsonXarelto | $103 | $16,78223 claims |
| MerckJanuvia | $125 | $11,49419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.
Other family medicine in Flushing
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.